ABSTRACT
Abstract Objective This study evaluated the risk of the hereditary breast and ovarian cancer (HBOC) syndrome in patients with breast cancer by using the Family History Screening 7 (FHS-7) tool, a validated low-cost questionnaire with high sensitivity able to screen the HBOC risk in the population. Methods Women diagnosed with breast cancer (n=101) assisted by the Unified Health System at the 8th Regional Health Municipal Office of the state of Paraná answered the FHS-7, and the results were analyzed using IBM SPSS Statistics for Windows, Version 25.0. software (IBM Corp., Armonk, NY, USA). Results The risk of HBOC was 19.80% (n=20). Patients at risk exhibited aggressive tumor characteristics, such as high-grade tumors (30%), presence of angiolymphatic emboli (35%), and premenopausal at diagnosis (50%). Significant associations between the prevalence of high-grade tumors were observed inwomen younger than 50 years at diagnosis with HBOC (p=0.003). Conclusion Our findings suggest a possible family inheritance associated with worse clinical features in women with breast cancer in this population, indicating that HBOC investigation can be initially performed with low-cost instruments such as FHS-7.
Resumo Objetivo Este estudo avaliou o risco da síndrome hereditária de câncer de mama e ovário (HBOC, na sigla em inglês) em pacientes com câncer de mama utilizando a ferramenta Familial History Screening 7 (FHS-7), um questionário validado de baixo custo e com alta sensibilidade capaz de rastrear o risco de HBOC na população. Métodos Mulheres diagnosticadas com câncer de mama (n=101) assistidas pelo Sistema Único de Saúde da 8ª Regional de Saúde do estado do Paraná responderam ao questionário FHS-7, e os resultados foram analisados pelo software IBM SPSS for Windows, Version 25.0. (IBM Corp., Armonk, NY, EUA). Resultados A ocorrência do risco de HBOC foi de 19,80% (n=20). Pacientes em risco exibiram características agressivas do tumor como tumores de alto grau (30%), presença de êmbolos angiolinfáticos (35%) e pré-menopausa ao diagnóstico (50%). Associações significantes foram observadas entre a prevalência de tumores de alto grau e diagnóstico abaixo de 50 anos no grupo HBOC (p=0.003). Conclusão Nossos achados sugerem uma possível herança familiar associada a piores características clínicas em mulheres com câncer de mama nessa população, indicando que a investigação de HBOC pode ser realizada, inicialmente, com instrumentos de baixo custo, como o FHS-7.
Subject(s)
Humans , Female , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/genetics , Breast Neoplasms/diagnosis , Breast Neoplasms/genetics , Hereditary Breast and Ovarian Cancer Syndrome , Mass Screening , Genetic Predisposition to Disease , Early Detection of CancerABSTRACT
Ovarian cancer is the presence of one or multiple tumors, which appears in one or both ovaries. These tumors are usually classified as epithelial and non-epithelial. Sex cord-stromal tumors are a group of benign and malignant neoplasms that develop from the sexual cord. Many are functional and therefore have hormonal secretions. Meigs syndrome is defined by the presence of pleural effusion and ascites in association with an ovarian tumor. We present a case of a 55 years old patient who was admitted due to a pelvic tumor, exudative pleural effusion that was difficult to manage, and ascites. A benign ovarian stromal tumor associated with elevated Ca 125 was diagnosed. After the management of the effusions, a 20x20x10 cm ovarian tumor resection was performed by laparotomy, and a transoperative report of a thecoma/fibroma type stromal tumor was received. Meigs syndrome occurs in 1% of ovarian tumors, being very rare before the third decade of life, the pathogenesis of ascites and pleural effusion could be related to the imbalance of hydrostatic forces between arterial flow and lymphovenous drainage culminating in a stromal transudate. Treatment of this syndrome should be focused on tumor debulking surgery and symptomatic treatments such as chest tubes and pleurodesis.
ABSTRACT
OBJECTIVE: To investigate the effect of inotodiol in inducing apoptosis of human ovary cancer cell line SKOV3, and its influence on the related apoptosis proteins such as Bcl-2, Bax and caspase-3. METHODS: Human ovary cancer SKOV3 cells were cultured in vitro. Cytotoxcity of inotodiol was determined by MTT assay. Morphological changes of apoptotic cells were observed by transmission electron microscope(TEM). Apoptotic rates of SKOV3 cells were confirmed by TUNEL(terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling) assay. The expressions of Bcl-2, Bax and caspase-3 were detected by immunocytochemical staining method. RESULTS: Inotodiol can inhibit the SKOV3 cells growth in a time-and dose-dependent manner. After treatment with inotodiol, SKOV3 cells showed typical apoptotic features under TEM. After human ovary cancer cell line SKOV3 were treated with inotodiol in concentration of 50 mg·L-1 for 24 and 48 h, their apoptotic rates were(21.91 ± 2.84)% and(43.83 ± 3.22)%, respectively. The apoptotic rate of SKOV3 cells induced by inotodiol increased in a time-dependent manner(P < 0.05). Immunocytochemical staining showed that the expression of Bcl-2 decreased obviously, whereas those of Bax and caspase-3 increased significantly in inotodiol group, compared with the control group. CONCLUSION: Inotodiol can inhibit the proliferation and induce the apoptosis of human ovary cancer cell line SKOV3 through up-regulation of Bax protein, down-regulation of Bcl-2 protein and activation of caspase apoptosis signal.
ABSTRACT
Ovarian cancer is the seventh most common cancer in the world and the fifth most common cause of death from cancer; it is responsible for over half of all deaths related to gynecological cancers. The presence of lymphatic metastasis is an important prognostic factor in ovarian cancer. Nodal metastases to the pelvic and the para-aortic lymph nodes are common, particularly in an advanced of the disease (stages III-IV). The finding of distant nodal metastasis, especially subclavian lymph node metastasis, from ovarian carcinoma is very uncommon. 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) or FDG-PET/computed tomography (CT) provides an improved imaging for detecting metastatic lymph nodes in patients with ovarian cancer. Immunohistochemically, ovarian carcinoma cells are positive for estrogen receptor, progesterone receptor, cancer antigen 125, Wilms' tumor 1 protein, and p53; they are negative for thyroid transcription factor (TTF-1) and caudal-related homeobox 2 (CDX-2). This report describes a Korean woman diagnosed with ovarian cancer with subclavian lymph node metastasis revealed by FDG PET/CT and verified by an immunohistochemical staining. Differentiating between the primary ovarian lesion and the metastatic lesion will allow the initiation of an appropriate treatment and help predict the prognosis.
Subject(s)
Female , Humans , Cause of Death , Estrogens , Genes, Homeobox , Immunohistochemistry , Lymph Nodes , Lymphatic Metastasis , Neoplasm Metastasis , Ovarian Neoplasms , Positron Emission Tomography Computed Tomography , Prognosis , Receptors, Progesterone , Thyroid Gland , Transcription Factors , Wilms TumorABSTRACT
Múltiples revisiones han estudiado el potencial coadyuvante en la radioterapia (RT) y quimioterapia (QT) en el tratamiento del cáncer de ovario, pero no se ha comparado adecuadamente la efectividad de la RT abdominal total (RTAT) versus nuevas drogas de QT. Tanto la cirugía como la QT previas a la RT aumentan la sobreviva total y libre de enfermedad, ya que radiosensibilizan al tumor favoreciendo su destrucción. Las distintas técnicas de RTAT no han demostrado diferencias significativas en la sobrevida ni en el control de la enfermedad, pero la RTAT de campos abierto si arrojó menor toxicidad tardía. En la actualidad nuevas técnicas como la IMRT (radioterapia de intensidad modulada) han comenzado a utilizarse con excelentes resultados. A pesar de los avances, muchos de estos pacientes desarrollan recurrencia intraabdominal, quedando fuera del rango terapéutico para QT y en dicho momento la RT puede ser utilizada también en forma paliativa con dosis grandes y únicas, cuidando la aparición de posibles complicaciones. Es probable que en el futuro se reintegre la RTAT en el tratamiento del cáncer de ovario de acuerdo a los hallazgos en el acto operatorio. Finalmente la RT/QT concomitantes, han demostrado su efecto sensibilizador sinergista y es esperable que con el tiempo se sigan integrando nuevas drogas con distintas interacciones como los taxanos y moléculas target. El tratamiento del cáncer de ovario sigue siendo esencialmente quirúrgico y con quimioterapia adyuvante, sin embargo también la radioterapia con quimioterapia han demostrado su efecto adyuvante. A pesar de ser una alternativa poco explorada en la actualidad es necesario estudiar prospectivamente el promisorio resultado de las nuevas técnicas de radioterapia en este tipo de pacientes.
Several studies have reviewed the potential coadjuvant of Radiotherapy (RT) and chemotherapy in the treatment of ovary cancer. However the effectiveness of total abdomen RT (RTAT) versus new QT drugs have not been adequately compared. Both surgery and QT prior to RT increase total and freedom from the disease since tumors become radiosensitive, thus favoring destruction. Diverse techniques such as IMRT (Intensity modulated radiation therapy) are being used with excellent results. Despite these advances, many of the patients develop intrabdominal recurrence leaving them out of the therapeutic scope/range for QT. RT may then be used as a palliative in big unique cases watching possible complications. RTAT may eventually be restarted in the treatment of ovary cancer depending on the findings during surgery. Finally, RT/QT concomitants have shown their effect in sensitivity and synergy and it is expected that new drugs with different interactions such as taxan and target molecules are added. Treatment of ovarian cancer remains essentially surgical and with chemotherapy, but both radio and chemotherapy has demonstrated their adjuvant effect. Despite being an unexplored alternative is necessary to study prospectively the promising results of new techniques of radiation therapy in these patients.
Subject(s)
Humans , Female , Ovarian Neoplasms/radiotherapy , Radiotherapy/methods , Combined Modality Therapy , Neoplasm Staging , Ovarian Neoplasms/surgery , Ovarian Neoplasms/drug therapy , Palliative Care , Radiotherapy, AdjuvantABSTRACT
Objective To know the influence of psychological nursing intervention for quality of life in patients with ovary cancer. Methods Divided 300 patients with ovary cancer into the intervention group and the control group randomly, there were 150 cases in the each group. Routine nursing cares was ued in the control group, the psychological nursing intervention was used in the intervention group in addi-tion. Compared the quality of life between the two groups by interviewed questionnair. Results After the nursing intervention, the indexes which can indicated the quality of life in the intervention group were bettez than those of in the control group significantly. Conclusions Psychological nursing intervention can ef-fective promote the quality of life of patients with ovary cancer.
ABSTRACT
PURPOSE: To date, anatomical imaging modalities of the pelvis and tumor markers have been the mainstay of surveillance for recurrent ovary cancer. This study aimed to assess the role of 18F-FDG PET/CT in evaluation of ovary cancer recurrences, especially in comparison with enhanced CT and tumor marker CA 125. Materials and METHODS: 73 patients who had PET/CT scan for restaging of confirmed ovary cancer, and additional imaging with enhanced CT of the pelvis within one month were included. CA 125 level was available in all patients. From the PET/CT images, maximum standard uptake values (SUVmax) of suspected recurrence sites were recorded. Confirmation was available through re-operation or biopsy in 26 cases, and clinical assessment with series of follow-up images in 47. RESULTS: PET/CT had 93% sensitivity and 88% specificity for detecting recurrent ovary cancer. Enhanced CT of pelvis had sensitivity and specificity of 83% and 88%, and CA 125 50% and 95%. CONCLUSION: PET/CT has higher sensitivity for detecting recurrent ovary cancer compared to enhanced CT though the differences were not significant. PET/CT has significantly higher sensitivity than CA 125. However, the three tests all agreed in only 43% of the recurrence cases, and recurrence should be suspected when any of the tests, especially PET/CT, show positive findings.
Subject(s)
Female , Humans , Biopsy , Fluorodeoxyglucose F18 , Follow-Up Studies , Ovarian Neoplasms , Ovary , Pelvis , Recurrence , Sensitivity and Specificity , Biomarkers, TumorABSTRACT
Objective To explore the function of BCRP in ovary cancer and establisment of BCRP expressing ovary cancer cell line 3AO/BCRP.Methods We construct the BCRP expressing cell line 3AO/BCRP.Extract the total RNA of MCF-7 cells,clone the whole length of BCRP gene by RT-PCR and ligate the gene to pcDNA3.1(-),transfect the positive clones to 3AO cells and select positive cell clones with G418,identify the survival cells by MTT,efflux assay,western blot.Results The multidrug resistance index of 3AO/BCRP to mitoxantrone increased to 11.58 times;the efflux of 3AO/BCRP to mitoxantrone enhanced;the relative level of BCRP mRNA in 3AO/BCRP increased and western blot indicate that the 3AO/BCRP cells can express more protein than 3AO cells.Conclusion 3AO/BCRP is a reliable BCRP expressing cell model,the establishment of this cell line has laid basis for further study of the mechanism of BCRP.
ABSTRACT
Objective: To investigate the role of Bcl-XL siRNA in sensitizing ovary cancer cells for TRAIL-induced apoptosis and the underlying mechanisms.Methods: Western blotting analysis was performed to confirm whether Bcl-XL siRNA could effectively down-regulate Bcl-XL protein after SKOV3 cells were transfected with Bcl-XL siRNA and then the cells were treated with TRAIL.Flow cytometry analysis and cell counting were used for assessment of apoptotic rate and survival rate,respectively.Western blotting analysis was performed to determine the changes of apoptosis-related protein in SKOV3 cells.Results: Compared with control group,Bcl-XL siRNA transfection effectively down-regulated the expression of Bcl-XL protein and suppressed the growth of SKOV3 cells;the suppression peaked at 96 h after transfection,being 43.9% that of the control group(P
ABSTRACT
Objective To investigate the clinical and pathological features of gastric cancer with ovarian metastasis and to analyze the reasons for its misdiagnosis. Methods There were 52 cases of gastric cancer with ovarian metastasis who had pathologic diagnoses from Jan. 1990 to Jun. 2004, whose clinical datum, pathological classification and the reasons for misdiagnosis were reviewed retrospectively and analyzed. Results The average age of the patients was 40.15?1.28 ( the ages ranging from 22 to 64 ). These patients's first symptoms and signs often were a metastatic ovary cancer. The main ultrasonographic findings were either a complex type of mass with both solid and cystic characteristics or only solid one, most of which accompany hydroperitonia, and among them metastatic ovary tumors on both sides reached 76.9 %. The serum CA125 levels increased, amounting to ( 99.85?14.23)U/mL on the average. It was greatly lower than a primary ovarian cancer(P
ABSTRACT
The purpose of this study was to review the clinical features, histological types and the mode of treatment of malignant gynecologic tumors. Retrospective reviews of the medical recordings for 75 cases with malignant gynecologic tumors in department of Obstetrics and Gynecology, Kuri hospital Hanyang University from July. 1, 1995 to Jun. 30. 2000. We analysed clinical characteristics, stage, histopathologic type and treatment modality. Of 75 cases, 44 cases were carcinoma of the uterine cervix, 21 cases were ovarian cancer and 10 cases were uterine cancer. The mean age of cervix cancer is 53.3 years, ovarian cancer is 50.9 years and uterine cancer is 49.5 years old. The main treatment modality of cervix and uterine cancer were surgery followed radiotherapy and ovary cancer was surgery plus adjuvant chemotherapy. However, as the number of patients were small in our study, further study with large number of patients are warranted.